Our strategy

The key components of Isofol’s strategic plan for value creation are to strengthen the evidence platform for arfolitixorin with new clinical data while advancing the drug candidate toward registration, maximize the potential of our strategic partnerships and collaborations, and continue building trust among investors and other stakeholders.

The foundation of our strategic plan is to generate new efficacy data for arfolitixorin by completing the ongoing phase Ib/II trial in an efficient and time-optimized manner in collaboration with world-leading clinical experts. The study lays a solid base for further development and upcoming regulatory approval processes. 

By nurturing collaborations with clinical experts and partner companies, we are strengthening the foundation for continued clinical development and commercialization of arfolitixorin. Simultaneously, we are building confidence in Isofol as an organization through transparent and open dialogue with shareholders, potential investors, and partners. We maintain high standards of regulatory compliance and focus on disciplined cost management, consistently prioritizing value-creating activities.

Our core values

Isofol’s core values are care, integrity, urgency and cooperation – guiding how we work together with partners and collaborators to bring our drug candidate to market as quickly as possible with deep consideration for patients, without compromising safety and integrity. The sooner arfolitixorin becomes an approved drug, the sooner we can achieve our goal: to give more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life.